AAN.com
Quick search in Citations
AnywhereCitation
Advanced Search
Trending Terms:
Articles
February 25, 2015

Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma

Agnieszka Korfel, MD, Eckhard Thiel, MD, Peter Martus, PhD, Robert Möhle, MD, Frank Griesinger, MD, Michael Rauch, MD, Alexander Röth, MD, Bernd Hertenstein, MD, Thomas Fischer, MD, Thomas Hundsberger, MD, Hans G. Mergenthaler, MD, Christian Junghanß, MD, Tobias Birnbaum, MD, Lars Fischer, MD, Kristoph Jahnke, MD, Ulrich Herrlinger, MD, Patrick Roth, MD, Michael Bamberg, MD, Torsten Pietsch, MD, and Michael Weller, MDAuthors Info & Affiliations
March 24, 2015 issue
84 (12) 1242-1248
https://doi.org/10.1212/WNL.0000000000001395
Letters to the Editor
Get Access

Abstract

Objective:

This is the final report of a phase III randomized study to evaluate whole-brain radiotherapy (WBRT) in primary therapy of primary CNS lymphoma (PCNSL) after a median follow-up of 81.2 months.

Methods:

Patients with newly diagnosed PCNSL were randomized to high-dose methotrexate (HDMTX)–based chemotherapy alone or followed by WBRT. We hypothesized that the omission of WBRT would not compromise overall survival (OS; primary endpoint), using a noninferiority design with a margin of 0.9.

Results:

In the per-protocol population (n = 320), WBRT nonsignificantly prolonged progression-free survival (PFS) (median 18.2 vs 11.9 months, hazard ratio [HR] 0.83 [95% confidence interval (CI) 0.65–1.06], p = 0.14) and significantly PFS from last HDMTX (25.5 vs 12.0 months, HR 0.65 [95% CI 0.5–0.83], p = 0.001), but without OS prolongation (35.6 vs 37.1 months, HR 1.03 [95% CI 0.79–1.35], p = 0.82). In the intent-to-treat population (n = 410), there was a prolongation by WBRT of both PFS (15.4 vs 9.9 months, HR 0.79 [95% CI 0.64–0.98], p = 0.034) and PFS from last HDMTX (19.4 vs 11.9 months, HR 0.72 [95% CI 0.58–0.89], p = 0.003), but not of OS (32.4 vs 36.1 months, HR 0.98 [95% CI 0.79–1.26], p = 0.98).

Conclusion:

Although the statistical proof of noninferiority regarding OS was not given, our results suggest no worsening of OS without WBRT in primary therapy of PCNSL.

Classification of evidence:

This study provides Class II evidence that in PCNSL HDMTX-based chemotherapy followed by WBRT does not significantly increase survival compared to chemotherapy alone. The study lacked the precision to exclude an important survival benefit or harm from WBRT.

Get full access to this article

View all available purchase options and get full access to this article.

Get Access

Supplementary Material

File (table_e-1.pdf)
File (wnl.0000000000001407.pdf)

REFERENCES

1.
Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010;11:1036–1047.
PubMed
Google Scholar
2.
Omuro A, Taillandier L, Chinot O, et al. Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? J Neurooncol 2011;104:323–330.
PubMed
Google Scholar
3.
Ekenel M, Iwamoto FM, Ben-Porat LS, et al. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer 2008;113:1025–1031.
PubMed
Google Scholar
4.
Omuro AM, Ben-Porat LS, Panageas KS, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 2005;62:1595–1600.
PubMed
Google Scholar
5.
Correa DD, Shi W, Abrey LE, et al. Cognitive functions in primary CNS lymphoma after single or combined modality regimens. Neuro Oncol 2012;14:101–108.
PubMed
Google Scholar
6.
Doolittle ND, Korfel A, Lubow M, et al. Long-term cognitive function, neuroimaging and quality of life in primary CNS lymphoma. Neurology 2013;81:84–92.
PubMed
Google Scholar
7.
Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000;18:3144–3150.
PubMed
Google Scholar
8.
Gavrilovic IT, Hormigo A, Yahalom J, et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006;24:4570–4574.
PubMed
Google Scholar
9.
Kasenda B, Schorb E, Fritsch K, et al. Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma: a long-term follow-up study. Ann Oncol 2012;23:2670–2675.
PubMed
Google Scholar
10.
Harder H, Holte H, Bromberg JE, et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 2004;62:544–547.
PubMed
Google Scholar
11.
Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol 2013;31:3971–3979.
PubMed
Google Scholar
12.
Roth P, Martus P, Kiewe P, et al. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology 2012;79:890–896.
PubMed
Google Scholar
13.
Camilleri-Broet S, Criniere E, Broet P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006;107:90–196.
Google Scholar
14.
Rubenstein JL, Fridlyand J, Shen A, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood 2006;107:3716–3723.
PubMed
Google Scholar
15.
Berghoff AS, Ricken G, Widhalm G, et al. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL). Clin Neuropathol 2014;33:42–49.
PubMed
Google Scholar

Information & Authors

Information

Published In

Neurology®
Volume 84 • Number 12 • March 24, 2015
Pages: 1242-1248

Copyright

© 2015 American Academy of Neurology.

Publication History

Received: July 24, 2014
Accepted: November 18, 2014
Published online: February 25, 2015
Published in print: March 24, 2015

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

Agnieszka Korfel, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
Mundipharma
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Mundipharma, Riemser, Pfizer
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Eckhard Thiel, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
Pfizer, Amgen, Celgene
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Pfizer, Amgen, Celgene
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
Pfizer, Amgen, Celgene
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Pfizer, Amgen, Celgene
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Peter Martus, PhD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
(1) Commercial entity: Data Safety Monitoring Boards (oncological study, private sponsor) more detailed information not possible as ongoing study (2) Commercial entity: Data Safety Monitoring Boards (oncological study, private sponsor) more detailed information not possible as ongoing study
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Robert Möhle, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
(1) Amgen GmbH
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
(1) Deutsche Jos? Carreras Leuk?mie-Stiftung (DJCLS R08/24v)
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Frank Griesinger, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
Commercial Roche Pfizer Novartis Lilly Astra Zeneca Boehringer Ingelheim non profit entity: IQWIG (Germany)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Commercial: Pfizer Novartis Astra Zeneca Boehringer Ingelheim
Editorial Boards:
1.
MEMO Frontiers in Oncology
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Michael Rauch, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Alexander Röth, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
Served on the scientific advisory board for Alexion Pharmaceuticals (2010-2014)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Received lecture fees from Alexion Pharmaceuticals (2010-2014)
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Research support from Alexion Pharmaceuticals and Geron.
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Bernd Hertenstein, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Thomas Fischer, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
Commercial entity (Novartis)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Commercial entity Novartis), travel funding, honoraria
Editorial Boards:
1.
Annals of Haematology, Editorial Board
Patents:
1.
Moguntinones in neoplasia
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Commercial entity (Novartis)
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
DFG SFB-854 BMBF JAK-Sys BMBF AML e.bio
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Else Kr?ner Fresenius Stiftung
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Thomas Hundsberger, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
(1)Roche, Switzerland (2)MSD, Switzerland (3) Genzyme, Switzerland (4) Baxter, Switzerland
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Genzyme, Switzerland
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Baxter, Switzerland
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Hans G. Mergenthaler, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
(1) Lilly
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Lilly (2) medac
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Christian Junghanß, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Tobias Birnbaum, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Lars Fischer, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Kristoph Jahnke, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Ulrich Herrlinger, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
(1) Roche Pharmaceuticals (2) Mundipharma
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Roche Pharmaceuticals, Speaker honoraria (2) Medac, Speaker honoraria (3) Mundipharma, Speaker honoraria
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
Therapie und Verlauf Neurologischer Erkrankungen, Chapter
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
see above at 3.
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Roche Pharmaceuticals
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Patrick Roth, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
Served on advisory boards for Roche, MSD and Molecular Partners (2011-2014)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Roche, travel grant
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Michael Bamberg, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
Trumpf (non-profit)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Der Onkologe
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Universit?tsklinikum T?bingen
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Torsten Pietsch, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author
Michael Weller, MD
From the Department of Hematology, Oncology and Tumor Immunology (A.K., E.T., L.F., K.J.), Charité Berlin; the Departments of Clinical Epidemiology and Applied Biostatistics (P.M.) and Hematology and Oncology (R.M.), University Tübingen; the Department of Radiotherapy and Medical Oncology (F.G.), Pius Hospital Oldenburg; the Department of Neurology (M.R.), Protestant Hospital Bielefeld; the Department of Hematology (A.R.), University Hospital Essen; the Department of Internal Medicine (B.H.), Hospital Bremen Center; the Department of Hematology and Oncology (T.F.), University Hospital Magdeburg; the Department of Neurology (T.H.), University Hospital Mainz; the Department of Hematology and Oncology (H.G.M.), Klinikum Stuttgart; the Department of Hematology and Oncology (C.J.), University Hospital Rostock; the Department of Neurology (T.B.), University Hospital Munich LMU; the Departments of Neurology (U.H., P.R., M.W.) and Radiation Oncology (M.B.), University Hospital Tübingen; the Department of Neurology (U.H.), University Bonn, Germany; the Department of Neurology (P.R., M.W.), University Hospital Zurich, Switzerland; and the Institute of Neuropathology (T.P.), University Hospital Bonn, Germany.
Disclosure
Scientific Advisory Boards:
1.
Roche, Merck Serono, MSD, Antisense Pharma, Magforce, Isarna, Pfizer, Teva
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Roche, Merck Serono, MSD, Celldex, Isarna, Magforce, Pfizer, Roche, Teva
Editorial Boards:
1.
European Editor, Neuro-Oncology; Editorial Boards: Brain, Glia, Journal of Clinical Oncology, Journal of Neuro-Oncology, Journal of Neurochemistry, Cellular Physiology & Biochemistry
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Bayer, MSD, Roche, Merck Serono, Acceleron, Alpinia Institute, PIQUR, Bayer
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
View all articles by this author

Notes

Correspondence to Dr. Korfel: [email protected]
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Author Contributions

A. Korfel designed and wrote the study protocol, contributed patients to the trial, and wrote and approved the report. E. Thiel designed and wrote the study protocol, contributed patients to the trial, and approved the report. P. Martus performed the statistical analyses and wrote and approved the report. R. Möhle contributed patients to the trial and approved the report. F. Griesinger contributed patients to the trial and approved the report. M. Rauch contributed patients to the trial and approved the report. A. Röth contributed patients to the trial and approved the report. B. Hertenstein contributed patients to the trial and approved the report. T. Fischer contributed patients to the trial and approved the report. T. Hundsberger contributed patients to the trial and approved the report. H.-G. Mergenthaler contributed patients to the trial and approved the report. C. Junghanß contributed patients to the trial and approved the report. T. Birnbaum contributed patients to the trial and approved the report. L. Fischer contributed patients to the trial and approved the report. K. Jahnke contributed patients to the trial and approved the report. U. Herrlinger designed and wrote the study protocol, contributed patients to the trial, and approved the report. P. Roth contributed patients to the trial and approved the report. M. Bamberg designed and wrote the study protocol, was responsible for central review of radiation oncology, and approved the report. T. Pietsch was responsible for central review of neuropathology and approved the report. M. Weller designed and wrote the study protocol, contributed patients to the trial, and wrote and approved the report.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

Study Funding

Supported by the German Cancer Aid grant 70-2838-Th.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
    • Susan Y Wu,
    • Steve E Braunstein,
    • James L Rubenstein,
    • Penny K Sneed,
    Stereotactic Radiosurgery for Primary Central Nervous System Lymphoma, Cureus, (2023).https://doi.org/10.7759/cureus.34817
    Crossref
    • Gabriela Villanueva,
    • Martin Guscott,
    • Paula Schaiquevich,
    • Claudia Sampor,
    • Ryan Combs,
    • Nicolás Tentoni,
    • Miriam Hwang,
    • Jennifer Lowe,
    • Scott Howard,
    A Systematic Review of High-Dose Methotrexate for Adults with Primary Central Nervous System Lymphoma, Cancers, 15, 5, (1459), (2023).https://doi.org/10.3390/cancers15051459
    Crossref
    • Alexandre Bertucci,
    • Vincent Harlay,
    • Olivier Chinot,
    • Emeline Tabouret,
    Primary central nervous system lymphoma (PCNSL) in older patients, Current Opinion in Oncology, 35, 5, (373-381), (2023).https://doi.org/10.1097/CCO.0000000000000981
    Crossref
    • Venkada Manickam Gurusamy,
    • Saju Raveendran Divakar,
    • Suparna Halsnad Chandramouli,
    • Beena Kunheri,
    • Hissa Hussain Al-Abdulla,
    • Ghazia Shaikh,
    • Rajiv Chaudary Apsani,
    • Mohamed Riyaz Poolakundan,
    • Palmira Caparrotti,
    • Rabih Wafiq Hammoud,
    • Noora Al-Hammadi,
    The role of radiotherapy in newly diagnosed primary CNS lymphoma: A descriptive review and a pragmatic approach to clinical practice, Clinical and Translational Radiation Oncology, 39, (100559), (2023).https://doi.org/10.1016/j.ctro.2022.12.002
    Crossref
    • Xuefei Sun,
    • Liwei Lv,
    • Yuchen Wu,
    • Qu Cui,
    • Shengjun Sun,
    • Nan Ji,
    • Yuanbo Liu,
    Challenges in the management of primary central nervous system lymphoma, Critical Reviews in Oncology/Hematology, 188, (104042), (2023).https://doi.org/10.1016/j.critrevonc.2023.104042
    Crossref
    • Tamer Othman,
    • Michelle A. Quan,
    • Shiliang Zhang,
    • Daria Gaut,
    • Patricia A. Young,
    • Omar Mahmood,
    • Haifaa Abdulhaq,
    • Kevin Shieh,
    • Jack Reid,
    • Elizabeth A Brem,
    • Nisha Hariharan,
    • Benjamin Heyman,
    • Joseph Tuscano,
    Impact of Thiotepa-Based Autologous Hematopoietic Cell Transplantation in Primary Central Nervous System Lymphoma in First Complete Remission: A University of California Hematologic Malignancies Consortium Retrospective Analysis, Clinical Lymphoma Myeloma and Leukemia, (2023).https://doi.org/10.1016/j.clml.2023.06.003
    Crossref
    • Ahmad N. Kassem,
    • David M. Peereboom,
    Primary Central Nervous System Lymphoma: Neuro-Oncologic Approach, Ocular and Adnexal Lymphoma, (93-101), (2023).https://doi.org/10.1007/978-3-031-24595-4_11
    Crossref
    • Jing Liu,
    • Jiayuan Guo,
    • Xuefei Sun,
    • Yuanbo Liu,
    • Chunji Gao,
    Efficacy and Safety of Autologous Stem-Cell Transplantation as Part of First-Line Treatment for Newly Diagnosed Primary Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis, Frontiers in Oncology, 11, (2022).https://doi.org/10.3389/fonc.2021.799721
    Crossref
    • Xin Cheng,
    • Haoran Chen,
    • Chongran Sun,
    • Buyi Zhang,
    • Jianmin Zhang,
    • Yongjie Wang,
    Whether surgical resection or biopsy makes difference in single lesion primary central nervous system lymphoma: a single center retrospective cohort study, BMC Neurology, 22, 1, (2022).https://doi.org/10.1186/s12883-022-02930-9
    Crossref
    • Anna M Laucis,
    • Katherine Selwa,
    • Yilun Sun,
    • Michelle M Kim,
    • Kyle C Cuneo,
    • Theodore S Lawrence,
    • Daniel R Wahl,
    • Larry Junck,
    • Yoshie Umemura,
    Efficacy and toxicity with radiation field designs and concurrent temozolomide for CNS lymphoma, Neuro-Oncology Practice, 9, 6, (536-544), (2022).https://doi.org/10.1093/nop/npac052
    Crossref
  11. See more

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Save for later Item saved, go to cart
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share

View full text|Download PDF